BCL2 and B-cell chronic lymphocytic leukemia: The recent approval by the FDA of Venetoclax, a BH3-mimetic Bcl-2 inhibitor, for the treatment of Chronic Lymphocytic Leukemia [2] has fueled interest in understanding the mechanisms that regulate the interactions between these proteins.